HC Wainwright Reaffirms Buy Rating for PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology (NASDAQ:PDSB - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $21.00 price objective on the stock.

Separately, Alliance Global Partners upgraded PDS Biotechnology to a "strong-buy" rating in a report on Wednesday, August 21st. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $14.25.

PDS Biotechnology Stock Down 0.3 %

Shares of PDSB stock traded down $0.01 on Thursday, hitting $3.11. The stock had a trading volume of 263,426 shares, compared to its average volume of 618,176. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.45. PDS Biotechnology has a one year low of $2.53 and a one year high of $6.85. The business has a 50 day moving average price of $3.27 and a 200 day moving average price of $3.27. The company has a market cap of $114.07 million, a PE ratio of -2.29 and a beta of 1.90.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.08. During the same quarter in the prior year, the company earned ($0.37) EPS. Research analysts anticipate that PDS Biotechnology will post -1.24 earnings per share for the current fiscal year.

Institutional Trading of PDS Biotechnology

A number of institutional investors have recently made changes to their positions in the business. Kathleen S. Wright Associates Inc. acquired a new stake in PDS Biotechnology in the 1st quarter worth approximately $28,000. Tempus Wealth Planning LLC purchased a new stake in shares of PDS Biotechnology in the 2nd quarter valued at $55,000. Ground Swell Capital LLC acquired a new stake in shares of PDS Biotechnology in the second quarter worth $67,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of PDS Biotechnology during the second quarter worth $115,000. Finally, Squarepoint Ops LLC acquired a new position in PDS Biotechnology during the second quarter valued at $120,000. Institutional investors and hedge funds own 26.84% of the company's stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.